AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Richmond Commences Drilling Program at Aguara East
Thu 26 Feb 26, 12:00 PMWill PolyNovo’s (ASX:PNV) New Board Addition Shape Its U.S. Medtech Strategy?
Sun 19 Oct 25, 08:08 AM1 Surging Stock with Exciting Potential and 2 to Avoid
Fri 23 May 25, 04:41 AM1 Unpopular Stock that Should Get More Attention and 2 to Brush Off
Tue 20 May 25, 04:35 AMPatient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest
Thu 15 May 25, 03:34 AM3 Profitable Stocks to Consider Right Now
Tue 06 May 25, 04:31 AMIs It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend?
Sat 03 May 25, 01:44 PMThis ResMed Insider Reduced Their Stake By 72%
Fri 02 May 25, 01:00 PM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | 1101.66M | 960.48M | 883.66M | 733.09M | 518.85M |
| Minority interest | - | - | - | - | - |
| Net income | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Selling general administrative | 874.00M | 739.37M | 670.39M | 676.69M | 645.01M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 2355.66M | 2024.31M | 1839.10M | 1717.79M | 1536.59M |
| Reconciled depreciation | 197.56M | 193.84M | 191.52M | 181.37M | 150.79M |
| Ebit | 1141.97M | 1000.29M | 903.68M | 809.66M | 579.26M |
| Ebitda | 1339.54M | 1194.13M | 1112.54M | 989.83M | 843.50M |
| Depreciation and amortization | 197.56M | 193.84M | 208.86M | 180.17M | 264.24M |
| Non operating income net other | - | - | - | -36.19400M | -24.26000M |
| Operating income | 1131.87M | 1000.29M | 903.68M | 809.66M | 579.26M |
| Other operating expenses | 3071.00M | 2577.84M | 2284.47M | 2147.95M | 1970.59M |
| Interest expense | 47.38M | 22.31M | 23.99M | 40.38M | 36.16M |
| Tax provision | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M |
| Interest income | 44.72M | 43.00M | 34.83M | 63.08M | 2.30M |
| Net interest income | -47.37900M | -22.31200M | -23.62700M | -39.35600M | -33.85700M |
| Extraordinary items | - | - | - | - | -6.65400M |
| Non recurring | - | - | - | -0.60000M | 56.72M |
| Other items | - | - | - | - | - |
| Income tax expense | 204.11M | 181.05M | 409.16M | 111.41M | 114.25M |
| Total revenue | 4222.99M | 3578.13M | 3196.82M | 2957.01M | 2606.57M |
| Total operating expenses | 1203.66M | 1024.03M | 926.75M | 908.73M | 900.60M |
| Cost of revenue | 1867.33M | 1553.82M | 1357.72M | 1239.23M | 1069.99M |
| Total other income expense net | -2.95400M | -39.80300M | -20.01600M | -76.57100M | -60.41600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Net income applicable to common shares | 897.56M | 779.44M | 780.39M | 621.67M | 404.59M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 6751.71M | 5095.85M | 4728.12M | 4587.38M | 4107.68M |
| Intangible assets | 552.34M | 345.94M | 392.58M | 448.17M | 521.95M |
| Earning assets | - | - | - | - | - |
| Other current assets | 437.02M | 337.91M | 208.15M | 168.75M | 120.11M |
| Total liab | 2621.80M | 1735.10M | 1842.45M | 2090.35M | 2035.49M |
| Total stockholder equity | 4129.90M | 3360.75M | 2885.68M | 2497.03M | 2072.19M |
| Deferred long term liab | - | - | - | 13.01M | 11.38M |
| Other current liab | 437.88M | 389.62M | 628.56M | 335.11M | 339.61M |
| Common stock | 0.59M | 0.59M | 0.58M | 0.58M | 0.57M |
| Capital stock | 0.59M | 0.59M | 0.58M | 0.58M | 0.57M |
| Retained earnings | 4253.02M | 3613.74M | 3079.64M | 2832.99M | 2436.41M |
| Other liab | 315.19M | 160.03M | 172.55M | 221.57M | 220.64M |
| Good will | 2770.30M | 1936.44M | 1927.90M | 1890.32M | 1856.45M |
| Other assets | 261.31M | 202.29M | 240.82M | 145.60M | 144.35M |
| Cash | 227.89M | 273.71M | 295.28M | 463.16M | 147.13M |
| Cash and equivalents | - | 273.71M | 295.28M | 463.16M | 147.13M |
| Total current liabilities | 758.53M | 689.30M | 911.77M | 602.76M | 555.99M |
| Current deferred revenue | 138.07M | 108.67M | 109.61M | 98.62M | 88.67M |
| Net debt | 1352.02M | 643.84M | 498.44M | 836.11M | 1123.72M |
| Short term debt | 31.82M | 31.77M | 35.59M | 33.25M | 11.99M |
| Short long term debt | 9.90M | 9.92M | 12.00M | 11.99M | 11.99M |
| Short long term debt total | 1579.91M | 917.55M | 793.72M | 1299.26M | 1270.85M |
| Other stockholder equity | 148.83M | 59.18M | -1.05700M | -52.56200M | -111.78300M |
| Property plant equipment | 665.81M | 630.50M | 592.07M | 535.68M | 387.46M |
| Total current assets | 2367.83M | 1931.48M | 1574.76M | 1523.46M | 1145.37M |
| Long term investments | - | - | - | - | 52.10M |
| Net tangible assets | 807.26M | 1078.37M | 565.20M | 158.53M | -306.20600M |
| Short term investments | - | - | - | - | - |
| Net receivables | 704.91M | 575.95M | 614.29M | 474.64M | 528.48M |
| Long term debt | 1431.23M | 765.33M | 643.35M | 1164.13M | 1258.86M |
| Inventory | 998.01M | 743.91M | 457.03M | 416.92M | 349.64M |
| Accounts payable | 150.76M | 159.25M | 138.01M | 135.79M | 115.72M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -272.52800M | -312.74700M | -193.48700M | -283.98200M | -253.00900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.58M | 0.58M | 0.57M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | 2832.99M | 2436.41M |
| Treasury stock | - | - | -1623.25600M | -1623.25600M | -1623.25600M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 395.43M | 251.49M | 240.82M | 189.74M | 196.46M |
| Deferred long term asset charges | - | - | - | - | 45.48M |
| Non current assets total | 4383.88M | 3164.38M | 3153.37M | 3063.92M | 2962.32M |
| Capital lease obligations | 138.77M | 142.31M | 138.36M | 123.14M | - |
| Long term debt total | - | 765.33M | 643.35M | 1164.13M | 1258.86M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -1159.84500M | -13.92200M | -158.46200M | -46.01300M | -46.98100M |
| Change to liabilities | 31.34M | -247.63200M | 210.71M | -23.42400M | -27.27800M |
| Total cashflows from investing activities | -1159.84500M | -229.91800M | -158.46200M | -179.86100M | -1075.70600M |
| Net borrowings | 665.00M | 122.00M | -522.00000M | -94.01200M | 807.49M |
| Total cash from financing activities | 422.87M | -128.36300M | -764.63200M | -317.28600M | 580.64M |
| Change to operating activities | -138.12500M | -168.10900M | -58.15400M | -58.99900M | -47.57500M |
| Net income | 897.56M | 779.44M | 474.50M | 621.67M | 404.59M |
| Change in cash | -45.81900M | -21.56800M | -167.87800M | 316.03M | -41.57300M |
| Begin period cash flow | 273.71M | 295.28M | 463.16M | 147.13M | 188.70M |
| End period cash flow | 227.89M | 273.71M | 295.28M | 463.16M | 147.13M |
| Total cash from operating activities | 693.30M | 351.15M | 736.72M | 802.25M | 459.05M |
| Issuance of capital stock | 49.14M | 47.38M | 37.79M | 48.18M | 36.73M |
| Depreciation | 197.56M | 193.84M | 191.52M | 181.37M | 150.79M |
| Other cashflows from investing activities | -1025.84500M | -17.17600M | -41.63600M | -38.51800M | -960.01500M |
| Dividends paid | 258.28M | 245.34M | 226.71M | 225.09M | 211.71M |
| Change to inventory | -248.83300M | -311.68100M | -21.95400M | -69.88100M | -84.18800M |
| Change to account receivables | -106.51100M | 19.35M | -129.19500M | 54.38M | -18.01300M |
| Sale purchase of stock | 1070.00M | 47.38M | 90.00M | 1190.00M | -22.84400M |
| Other cashflows from financing activities | -32.99200M | 235.59M | -53.70900M | -46.36300M | 1490.22M |
| Change to netincome | 60.31M | 85.94M | 69.29M | 82.61M | 80.72M |
| Capital expenditures | 134.00M | 156.04M | 116.83M | 105.94M | 77.34M |
| Change receivables | - | - | - | 54.38M | -18.01300M |
| Cash flows other operating | - | - | - | -17.95700M | -47.57500M |
| Exchange rate changes | - | - | - | 10.92M | -5.56100M |
| Cash and cash equivalents changes | - | - | - | 316.03M | -41.57300M |
| Change in working capital | -462.12700M | -708.07600M | 1.41M | -97.92100M | -177.05400M |
| Stock based compensation | 71.14M | 65.26M | 63.93M | 57.56M | 52.07M |
| Other non cash items | -11.05000M | 20.69M | 8.67M | -0.00700M | -0.28600M |
| Free cash flow | 559.30M | 195.11M | 619.89M | 696.32M | 381.71M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RMD ResMed Inc |
-5.82 2.30% | 247.11 | 27.87 | 24.81 | 5.85 | 6.02 | 6.14 | 19.59 |
| ISRG Intuitive Surgical Inc |
-7.71 1.56% | 485.85 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.25 0.20% | 122.50 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
4.90 2.00% | 249.71 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.58 0.95% | 163.88 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
9001 Spectrum Center Boulevard, San Diego, CA, United States, 92123
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD | Founder & Non-Exec. Chairman | 1942 |
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Director | 1972 |
| Mr. Robert A. Douglas | Pres & COO | 1960 |
| Mr. Brett A. Sandercock | Chief Financial Officer | 1967 |
| Mr. David B. Pendarvis | Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. | 1959 |
| Mr. Kaushik Ghoshal | Pres of SaaS Bus. | 1968 |
| Ms. Urvashi Tyagi | Chief Technology Officer | NA |
| Ms. Constance C. Bienfait | Director of Investor Relations | NA |
| Ms. Amy Wakeham | VP of Investor Relations & Corp. Communications | NA |
| Ms. Vered Keisar | Chief People Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...